ITGB7抗体;ITGB7 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using ITGB7 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using ITGB7 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using ITGB7 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human endometrial cancer tissues using ITGB7 mouse mAb with DAB staining.    

  
  

The ITGB7 antibody targets the integrin beta-7 subunit (β7), a cell surface receptor critical for immune cell trafficking and adhesion. Integrins are heterodimeric proteins composed of α and β subunits. β7 pairs with α4 or αE subunits, forming α4β7 and αEβ7 integrins. α4β7 mediates lymphocyte homing to gut-associated lymphoid tissues (GALT) by binding to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), while αEβ7 facilitates retention of intraepithelial lymphocytes via interactions with E-cadherin.

ITGB7 is predominantly expressed on immune cells, including T and B lymphocytes, particularly those localized to mucosal surfaces. Its role in gut-specific immune responses has made it a focus in studying inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis. Therapeutic antibodies blocking α4β7 (e.g., vedolizumab) are used to dampen intestinal inflammation by inhibiting leukocyte migration.

Research also links ITGB7 to cancer progression, as tumor cells may exploit β7 integrins for metastasis. Antibodies against ITGB7 serve as tools to study these mechanisms or as potential therapeutics. However, their clinical application beyond IBD remains exploratory. Understanding ITGB7’s dual roles in immunity and pathology underscores its importance as a biomarker and therapeutic target in mucosal immunity and oncology.